Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unresectable Hepatocellular Carcinoma 1Stomatitis 1Respiratory Aspiration 1Recurrence 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Periodontitis 1Pain 1Ovariancancer 1Ovarian Neoplasms 1Non Small Cell Lung Caner 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myasthenia Gravis 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Calculi 1Immune Checkpoint Inhibitor-Induced Dermatitis 1Head and Neck Neoplasms 1Febrile Neutropenia 1Fatigue 1Dupuytren Contracture 1Depression 1

Interventions

Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Immune Checkpoint Inhibitor-Induced Dermatitis × Therapeutics × Clear all
NCT07530224 2026-04-15

JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis

Hangzhou Cancer Hospital

Phase 2 Not yet recruiting
35 enrolled

Immune Checkpoint Inhibitor-Induced Dermatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡